Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Allurion Technologies's Enterprise Value for the quarter that ended in Mar. 2026 was $34.51 Mil.
Allurion Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Allurion Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's EV-to-EBIT falls into.
Allurion Technologies's current Enterprise Value is $25.67 Mil.
Allurion Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allurion Technologies (ALUR) has a EV-to-EBIT of -0.81 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Allurion Technologies and its competitors. According to the industry distribution chart, Allurion Technologies ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Allurion Technologies' EV-to-EBIT too high?
Allurion Technologies' current EV-to-EBIT is -0.81. Based on the distribution chart, Allurion Technologies ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Allurion Technologies has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' EV-to-EBIT compare to ESMC and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Allurion Technologies ranks #999999 out of 475 companies for EV-to-EBIT. This places Allurion Technologies in the lower half of its industry. The industry median EV-to-EBIT is 18.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.38, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Allurion Technologies and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allurion Technologies's current EV-to-EBIT is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALUR) is currently considered Possible Value Trap. The stock's GF Value™ is $10.24, compared to a current price of $1.28 — trading 87.5% below its estimated fair value. The current EV-to-EBIT is -0.81. Allurion Technologies' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Allurion Technologies (ALUR), the current EV-to-EBIT is -0.81 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALUR) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $1.28 is trading 87.5% below its estimated GF Value™ of $10.24.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALUR:
EV-to-EBIT: -0.81
GF Value™: $10.24 vs. price of $1.28 (87.5% below fair value)
No single metric tells the full story. See the ALUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
23GF Score
Get the complete analysis for ALUR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALUR has been successfully added to your 
